Johnson and Johnson presents new IMAAVYÂ (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained dise

Barings Corporate Investors (MCI) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2025Q2
while the 0.14 debt-to-equity ratio provides stability, the fact that dividend payments of $9.2 million significantly exceed the $4.6 million in operating cash flow warrants caution regarding long-term payout sustainability.
Barings Corporate Investors (MCI) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Barings Corporate Investors (MCI) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q1 2025Latest | Feb 27, 2025 | $0.46 | $11M |
| Q3 2024 | Aug 15, 2024 | $0.42 | $10M |
| Q2 2024 | May 16, 2024 | $0.42 | $10M |
| Q1 2024 | Feb 26, 2024 | $0.49 | $11M |
Recent stock market news and headlines for Barings Corporate Investors (MCI)
Johnson and Johnson presents new IMAAVYÂ (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained dise

Key metrics vs top competitors for Barings Corporate Investors (MCI)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $17.34 | $354.99M | 9.91 | 5.1% | 82.2% | 10.41% | 9.05% | |
| $16.28 | $175.08M | 13.24 | -15.8% | 79.86% | 18.32% | — | |
| $6.42 | $138.75M | 10.35 | 121.65% | 21.93% | 3.58% | — | |
| $7.19 | $713.38M | 9.99 | 2.2% | 34.83% | 5.84% | — | |
| $4.75 | $192.85M | 3.89 | 36.55% | -19.55% | -3.39% | — | |
| $23.51 | $1.46B | 12.37 | 50.13% | 50.89% | 11.68% | — |
Barings Corporate Investors (MCI) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when MCI posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Barings Corporate Investors (MCI) stock FAQ — growth, dividends, profitability & financials explained
Barings Corporate Investors (MCI) reported $41.1M in revenue for fiscal year 2024.
Barings Corporate Investors (MCI) grew revenue by 5.1% over the past year. This is steady growth.
Yes, Barings Corporate Investors (MCI) is profitable, generating $32.0M in net income for fiscal year 2024 (82.2% net margin).
Yes, Barings Corporate Investors (MCI) pays a dividend with a yield of 9.05%. This makes it attractive for income-focused investors.
Barings Corporate Investors (MCI) has a return on equity (ROE) of 10.4%. This is reasonable for most industries.
Barings Corporate Investors (MCI) generated $12.7M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.